Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study

Conclusions: Solriamfetol may be a novel and effective treatment for the management of ADHD in adults. Further replication in larger trials is indicated.Trial Registration: ClinicalTrials.gov identifier: NCT04839562.PMID:37819836 | DOI:10.4088/JCP.23m14934

Source: Journal of Clinical Psychiatry - October 11, 2023 Category: Psychiatry Authors: Craig B H Surman Daniel M Walsh Nora Horick Maura DiSalvo Chloe Hutt Vater Daniel Kaufman Source Type: research